Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
PEL will explore the PLI scheme and apply if its beneficial.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
